In the Know: Healthcare News for March 28, 2022
NAMSA Announces Intent to Acquire CRO, ÅKRN GrandPad Purpose-Built Tablet for Seniors Now Available on Amazon.com St. Paul-Based Phraxis Inc. Raises $4.5M to Launch New Dialysis Tech Allina Health | Aetna Announces New CEO, Robert Wieland, MD Minneapolis Medical Device Industry Veteran Christine Horton Named Visura CEO Mayo Clinic Platform_Accelerate Program Begins with Four AI […]
HLT®, Inc. Gains FDA Approval for Two TAVR Clinical Studies
The studies will assess the performance of its HLT Meridian® TAVR® Valve System to treat aortic stenosis and aortic regurgitation for high-risk patients suffering from aortic disease MAPLE GROVE, Minn. (March 24, 2022) – HLT Inc., a Bracco Group Company and a leader in the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, announced today that it has received U.S. […]
HLT®, Inc. Names Dr. Satya Shreenivas as Chief Medical Officer
MAPLE GROVE, Minn. (Nov. 9, 2021) – HLT Inc., a Bracco Group Company, leading the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, has named Dr. Satya Shreenivas as its new chief medical officer. Dr. Shreenivas was most recently one of the primary structural heart physicians at The Christ Hospital and prior to that […]
In The Know: Healthcare News for June 7, 2021
Eden Prairie’s Miromatrix Becomes Latest Minnesota Company to File for an IPO Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients STERIS Completes the Acquisition of Cantel Medical Preceptis Medical Launches Next-Generation Hummingbird Tympanostomy Tube System for In-Office Pediatric Ear Tube Procedures HLT, Inc. Names David Elizondo President and […]
HLT, Inc. Names David Elizondo President and CEO
Veteran Medical Device Executive Set to Lead Transcatheter Valve Company Organization MAPLE GROVE, Minn. (June 2, 2021) – HLT Inc., a Bracco Group Company, leading the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, has appointed David Elizondo as president and CEO. In his new role, Elizondo will lead the development and execution of HLT’s operational and […]
